Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities

Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery ...
MPR

First Treatment for Menkes Disease: FDA Approves Copper Histidinate

Zycubo is a copper replacement therapy administered via subcutaneous injection to bypass impaired GI absorption in patients with Menkes disease.
Medical Dialogues

Zydus-Owned Sentynl Gets USFDA Nod for First-Ever Menkes Disease Treatment ZYCUBO

ZYCUBO is a subcutaneous injectable formulation of copper histidinate designed to restore copper homeostasis and maintain adequate copper levels in patients with Menkes disease.
The Manila Times

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab ...
The Pharma Letter

LIB Therapeutics

A privately held biopharmaceutical company based in the United States. Its development and planned commercialization activities are oriented toward major lipid-management markets, with regional ...
The Manila Times

Skye Provides 2026 Corporate Outlook

CBeyondTM Phase 2a 26-week extension data update and interim results expected Q1 2026. CBeyond Phase 2a Data Monitoring ...

Halozyme Therapeutics, Inc.: Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE for Obesity

Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Halozyme ...
Stocktwits on MSN

FBIO stock surges 12% pre-market after it wins FDA approval for rare pediatric Menkes disease

The FDA’s green light comes after Sentynl Therapeutics, fully owned by Zydus Lifesciences, assumed responsibility for ...
American Association of Individual Investors

Why Xeris Biopharma Holdings, Inc.’s (XERS) Stock Is Up 13.04%

As of Thursday, January 08, Xeris Biopharma Holdings, Inc.’s XERS share price has surged by 13.04%, which has investors questioning if this is right time to sell.
Le Lézard

Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Halozyme Therapeutics, Inc. today announced the Company entered into a global collaboration and exclusive license agreement ...
Managed Healthcare Executive

Evolving treatment paradigms in hemophilia: Written recap

Hemophilia A and B involve deficiencies in coagulation factors VIII and IX, with traditional treatments requiring frequent infusions. Nonfactor therapies, including Hemlibra and rebalancing agents, ...

Halozyme Therapeutics, Inc.: Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE

Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics ...